

Goat Anti-VHL Antibody
Peptide-affinity purified goat antibody
Catalog # AF2146a

Specification

Goat Anti-VHL Antibody - Product Information

Application	WB, EIA
Primary Accession	P40337
Other Accession	NP_937799 , 7428 , 22346 (mouse) , 24874 (rat)
Reactivity	Human, Mouse, Rat
Predicted	Dog
Host	Goat
Clonality	Polyclonal
Concentration	100ug/200ul
Isotype	IgG
Calculated MW	24153

Goat Anti-VHL Antibody - Additional Information

Gene ID 7428

Other Names

Von Hippel-Lindau disease tumor suppressor, Protein G7, pVHL, VHL

Format

0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Goat Anti-VHL Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Goat Anti-VHL Antibody - Protein Information

Name VHL

Function

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex (PubMed: [10944113](http://www.uniprot.org/citations/10944113) target="_blank">10944113, PubMed: [17981124](http://www.uniprot.org/citations/17981124) target="_blank">17981124, PubMed: [19584355](http://www.uniprot.org/citations/19584355) target="_blank">19584355). Seems to act as a target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions

(PubMed:10944113, PubMed:17981124). Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases (PubMed:10944113, PubMed:17981124). Ubiquitinates, in an oxygen-responsive manner, ADRB2 (PubMed:19584355). Acts as a negative regulator of mTORC1 by promoting ubiquitination and degradation of RPTOR (PubMed:34290272).

Cellular Location

[Isoform 1]: Cytoplasm. Cell membrane; Peripheral membrane protein. Endoplasmic reticulum. Nucleus. Note=Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated (PubMed:9751722) Colocalizes with ADRB2 at the cell membrane (PubMed:19584355)

Tissue Location

Expressed in the adult and fetal brain and kidney.

Goat Anti-VHL Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Goat Anti-VHL Antibody - Images



AF2146a (0.01 µg/ml) staining of Human Ovary lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.



AF2146a (1.5ug/ml) as the reporter with EB002014 as the capture rabbit antibody (2.5ug/ml).

Goat Anti-VHL Antibody - Background

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Goat Anti-VHL Antibody - References

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Peñ̄a C, et al. Clin Cancer Res, 2010 Sep 14. PMID 20651059. Variation at the NFATC2 Locus Increases the Risk of Thiazolinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086. A Large-scale genetic association study of esophageal adenocarcinoma risk. Liu CY, et al. Carcinogenesis, 2010 Jul. PMID 20453000. Clinical and molecular features of familial and sporadic cases of von Hippel-Lindau disease from Mexico. Chacon-Camacho OF, et al. Clin Experiment Ophthalmol, 2010 Apr. PMID 20447124. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Montani M, et al. Am J Surg Pathol, 2010 Jun. PMID 20431476.